Ocrelizumab reduces progression of brain atrophy in patients with multiple sclerosis
Introduction: Multiple sclerosis (MS) is a clinical entity characterised by both inflammatory and neurodegenerative components. Ocrelizumab is an anti-CD20 monoclonal antibody that has demonstrated high clinical efficacy in controlling neuroinflammation, and evidence suggests it may also exert a ben...
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2026-04-01
|
| Seri Bilgileri: | Neurology Perspectives |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2667049625000341 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|